Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of Best Evidence Dosing Recommendations for Term and Preterm Neonates (NeoDose Project)

Autor: Hoop-Sommen, M.A. de, Zanden, T.M. van der, Allegaert, K., Flint, R.B., Simons, S.H., Wildt, S.N. de

Publikováno v: Neonatology, 120, 196-207
Neonatology, 120(2), 196-207. Karger
Neonatology, 120, 2, pp. 196-207

Many drugs are used off-label in neonates which leads to large variation in prescribed drugs and dosages in neonatal intensive care units (NICUs). The NeoDose project aimed to develop best evidence dosing recommendations (DRs) for term and preterm ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f984459f2ea48aef30c219b379df476
http://hdl.handle.net/2066/291538

Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants

Autor: Engbers, A.G.J., Flint, R.B., Völler, S., Reiss, I., Liem, K.D., Alffenaar, J.W.C., Tibboel, D., Simons, S., Knibbe, C.A.J., Bruggemann, R.J.

Publikováno v: Archives of Disease in Childhood, 107(4):archdischild-2021-322560, 400-406. BMJ Publishing Group
Archives of Disease in Childhood, 107, 4, pp. 400-406
Archives of Disease in Childhood, 107(4), 400-406. BMJ PUBLISHING GROUP
Archives of disease in childhood, 107(4), 400-406. BMJ PUBLISHING GROUP
Archives of Disease in Childhood, 107, 400-406

IntroductionFluconazole is an important antifungal in the prevention and treatment of invasive Candida infections in neonates, even though its use in preterm infants is still off-label. Here, we performed a population pharmacokinetic study on flucona

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::931882ae3498ce0a5c3219f3c38a645c
https://doi.org/10.1136/archdischild-2021-322560

The bioavailability and maturing clearance of doxapram in preterm infants

Autor: Flint, R.B., Simons, S.H.P., Andriessen, P., Liem, K.D., Degraeuwe, P.L.J., Reiss, I.K.M., Ter Heine, R., Engbers, A.G.J., Koch, B.C.P., Groot, R. de, Burger, D.M., Knibbe, C.A..J., Völler, S., DINO Research Group

Background Doxapram is used for the treatment of apnea of prematurity in dosing regimens only based on bodyweight, as pharmacokinetic data are limited. This study describes the pharmacokinetics of doxapram and keto-doxapram in preterm infants. Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______202::206f123f4fcbdf233030030848917612
https://hdl.handle.net/1887/139108

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.